ROCKET PHARMACEUTICALS, INC.
About ROCKET PHARMACEUTICALS, INC.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$223.1M
- Total assets
- $330.4M
- Market cap
- $300.3M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $231.7M
- Operating income
- -$231.7M
- Income tax
- $0
- Net income
- -$223.1M
- EPS (basic)
- $-2.01
- EPS (diluted)
- $-2.01
Balance sheet
- Total assets
- $330.4M
- Current assets
- $192.7M
- Total liabilities
- $53.2M
- Current liabilities
- $30.2M
- Shareholders’ equity
- $277.2M
Cash flow
- Operating cash flow
- -$190.0M
- Investing cash flow
- $103.8M
- Financing cash flow
- $148.0K
- Net cash flow
- -$86.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $300.3M
- EPS (diluted)
- $-2.01
- Shares outstanding
- 111.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 18, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $223.1M in FY2025.
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ROCKET PHARMACEUTICALS, INC..
Write a review
News about ROCKET PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
